Please login to the form below

Not currently logged in
Email:
Password:

infliximab

This page shows the latest infliximab news and features for those working in and with pharma, biotech and healthcare.

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

Pharma giants Johnson &Johnson (J&J) and Pfizer have privately resolved a prolonged lawsuit relating to alleged anticompetitive practices revolving around the biosimilar market for infliximab. ... As a result – Pfizer alleged – this restricted use of

Latest news

More from news
Approximately 15 fully matching, plus 125 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    Notably the biosimilar Renflexis (infliximab-abda) achieved a 70-80% price reduction to its reference product in both Norway and Denmark. ... The UK has been especially proactive with biosimilars. Three biologics there – infliximab, rituximab and

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s disease, while Pfizer was in an advanced stage of developing ... its own biosimilar for

  • The tipping point The tipping point

    For example, since 2015, when the first monoclonal antibody biosimilar, infliximab, was launched in Europe we have seen a notable increase in the overall use of infliximab. ... Driving disparity. If we look across Europe at biosimilar penetration, even

  • Building a bright future Building a bright future

    We have many examples where small molecule and biosimilars have improved uptake such as the case of infliximab in Norway, which was supported by the government that sponsored clinical trials showing

  • The reality of real-world evidence The reality of real-world evidence

    RWE data presented at ECCO this year showed that switching to the biosimilar Remsima (infliximab) from the originator had no negative effect on safety and efficacy in 10 real-world studies.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    Positive experience of using infliximab biosimilars in gastro infusion clinics has had a big impact on the overall confidence of biosimilars. ... However, positive experience of switching in other therapy areas especially gastro patients receiving

  • Innovation in pharma: the highs and lows of the current healthcare economy

    So far, the introduction of biosimilar medicines seems to be progressing at a pace (uptake of the biosimilar infliximab was at a national average of 79.7% earlier this year), but

  • Biosimilars: Getting the flock to market

    brands. Typically they are priced at a discount of 10-30%, and some infliximab biosimilars offer reductions of up to 60%. ... Last year an audit by the Royal College of Physicians showed that Remicade (infliximab) biosimilars were "safe, effective and

  • Infographic: RA Perceptions

    Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...